BIRC3 and B-cell chronic lymphocytic leukemia: The adoption of CIT regimens for CLL has led to the identification of several biomarkers of refractoriness to this therapeutic approach, including the unmutated status of immunoglobulin heavy-chain variable (IGHV) genes and genetic lesions of TP53, BIRC3 and NOTCH1 [24].